Table 3.
For patients with the largest brain metastasis over 1 cm: univariate and multivariate Cox regression analyses of covariables associated with survival after the diagnosis of brain metastasis.
| Univariate analyses | Multivariate analyses | |||
|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | |
| Age | ||||
| >65 vs. ≦65 | 1.32 (0.77 to 2.29) | 0.318 | ||
| Female vs. male | 0.59 (0.35 to 1) | 0.052 | ||
| Initial Clinical stage | ||||
| III–IV vs. I–II | 1.38 (0.5 to 3.81) | 0.538 | ||
| Initial Tumor classification | ||||
| III–IV vs. I–II | 0.92 (0.5 to 1.67) | 0.772 | ||
| Initial Nodal classification | ||||
| 2–3 vs. 0–1 | 1.67 (0.98 to 2.83) | 0.058 | 2.23 (1.27 to 3.92) | 0.005 |
| EGFR mutation | ||||
| Exon 19 or 21 | ||||
| Yes vs. no | 0.815 (0.43 to 1.55) | 0.533 | ||
| Exon 19 | ||||
| Yes vs. no | 0.68 (0.41 to 1.15) | 0.15 | ||
| Exon 20 | ||||
| Yes vs. no | 0.82 (0.372 to 1.81) | 0.622 | ||
| Exon 21 | ||||
| Yes vs. no | 1.12 (0.65 to 1.9) | 0.687 | ||
| Brain surgery | ||||
| Yes vs. no | 0.5 (0.3 to 0.84) | 0.008 | 0.49 (0.29 to 0.83) | 0.008 |
| RT boost dose >3750cGy | ||||
| Yes vs. no | 1.1 (0.65 to 1.85) | 0.726 | ||
| Number of lines of systemic chemotherapy | ||||
| >3 vs. 0–3 | 1.18 (0.53 to 2.61) | 0.684 | ||
| TKI name | ||||
| afatinib | ||||
| Yes vs. no | 1.16 (0.46 to 2.9) | 0.757 | ||
| erlotinib | ||||
| Yes vs. no | 0.57 (0.34 to 0.95) | 0.031 | 0.49 (0.29 to 0.85) | 0.011 |
| gefitinib | ||||
| Yes vs. no | 1.43 (0.83 to 2.48) | 0.199 | ||
| osimertinib | ||||
| Yes vs. no | 1.31 (0.41 to 4.19) | 0.655 | ||
| Number of lines of TKI | ||||
| >1 vs. 1 | 0.692 (0.4 to 1.2) | 0.192 | ||
| ECOG performance status | ||||
| 1 vs. 0 | 0.96 (0.57 to 1.62) | 0.889 | ||
| 2 vs. 0 | 0.59 (0.14 to 2.47) | 0.467 | ||
| Smoking status | ||||
| Former or current vs. never | 1.25 (0.71 to 2.2) | 0.434 | ||
| Symptomatic brain metastases | ||||
| Yes vs. no | 0.73 (0.31 to 1.71) | 0.471 | ||
| No. of brain metastases | ||||
| 2–3 vs. 1 | 1.62 (0.75 to 3.49) | 0.216 | ||
| >3 vs. 1 | 1.4 (0.58 to 3.39) | 0.451 | ||
| dsGPA | ||||
| 0.5–1.5 vs. 2–4 | 1.38 (0.74 to 2.55) | 0.311 | ||
Abbreviations: EGFR: epidermal growth factor receptor; RT: radiation therapy; TKI: tyrosine kinase inhibitor; ECOG: Eastern Cooperative Oncology Group; dsGPA: disease-specific Graded Prognostic Assessment.